These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 21188390)

  • 1. Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab.
    Formica V; Palmirotta R; Del Monte G; Savonarola A; Ludovici G; De Marchis ML; Grenga I; Schirru M; Guadagni F; Roselli M
    Int J Colorectal Dis; 2011 Feb; 26(2):143-51. PubMed ID: 21188390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer.
    Loupakis F; Ruzzo A; Salvatore L; Cremolini C; Masi G; Frumento P; Schirripa M; Catalano V; Galluccio N; Canestrari E; Vincenzi B; Santini D; Bencardino K; Ricci V; Manzoni M; Danova M; Tonini G; Magnani M; Falcone A; Graziano F
    BMC Cancer; 2011 Jun; 11():247. PubMed ID: 21669012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.
    Loupakis F; Cremolini C; Yang D; Salvatore L; Zhang W; Wakatsuki T; Bohanes P; Schirripa M; Benhaim L; Lonardi S; Antoniotti C; Aprile G; Graziano F; Ruzzo A; Lucchesi S; Ronzoni M; De Vita F; Tonini G; Falcone A; Lenz HJ
    PLoS One; 2013; 8(7):e66774. PubMed ID: 23861747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: results from the Nordic ACT trial.
    Hansen TF; Christensen Rd; Andersen RF; Garm Spindler KL; Johnsson A; Jakobsen A
    Int J Colorectal Dis; 2012 Jun; 27(6):715-20. PubMed ID: 22139032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G.
    Shitara K; Yonesaka K; Denda T; Yamazaki K; Moriwaki T; Tsuda M; Takano T; Okuda H; Nishina T; Sakai K; Nishio K; Tokunaga S; Yamanaka T; Boku N; Hyodo I; Muro K
    Cancer Sci; 2016 Dec; 107(12):1843-1850. PubMed ID: 27712015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
    Tsai HL; Lin CH; Huang CW; Yang IP; Yeh YS; Hsu WH; Wu JY; Kuo CH; Tseng FY; Wang JY
    Int J Clin Exp Pathol; 2015; 8(2):1900-10. PubMed ID: 25973082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab.
    Koutras AK; Antonacopoulou AG; Eleftheraki AG; Dimitrakopoulos FI; Koumarianou A; Varthalitis I; Fostira F; Sgouros J; Briasoulis E; Bournakis E; Bafaloukos D; Bompolaki I; Galani E; Kalogeras KT; Pectasides D; Fountzilas G; Kalofonos HP
    Pharmacogenomics J; 2012 Dec; 12(6):468-75. PubMed ID: 21844885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.
    Kang BW; Kim TW; Lee JL; Ryu MH; Chang HM; Yu CS; Kim JC; Kim JH; Kang YK; Lee JS
    Med Oncol; 2009; 26(1):32-7. PubMed ID: 18498064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer.
    Shigeta K; Hasegawa H; Okabayashi K; Tsuruta M; Ishii Y; Endo T; Ochiai H; Kondo T; Kitagawa Y
    Int J Cancer; 2016 Aug; 139(4):946-54. PubMed ID: 27061810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial.
    Ocvirk J; Brodowicz T; Wrba F; Ciuleanu TE; Kurteva G; Beslija S; Koza I; Pápai Z; Messinger D; Yilmaz U; Faluhelyi Z; Yalcin S; Papamichael D; Wenczl M; Mrsic-Krmpotic Z; Shacham-Shmueli E; Vrbanec D; Esser R; Scheithauer W; Zielinski CC
    World J Gastroenterol; 2010 Jul; 16(25):3133-43. PubMed ID: 20593498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial.
    Ulivi P; Scarpi E; Passardi A; Marisi G; Calistri D; Zoli W; Del Re M; Frassineti GL; Tassinari D; Tamberi S; Vertogen B; Amadori D
    J Transl Med; 2015 Aug; 13():258. PubMed ID: 26259598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab.
    Pentheroudakis G; Mavroeidis L; Papadopoulou K; Koliou GA; Bamia C; Chatzopoulos K; Samantas E; Mauri D; Efstratiou I; Pectasides D; Makatsoris T; Bafaloukos D; Papakostas P; Papatsibas G; Bombolaki I; Chrisafi S; Kourea HP; Petraki K; Kafiri G; Fountzilas G; Kotoula V
    Clin Colorectal Cancer; 2019 Dec; 18(4):e370-e384. PubMed ID: 31402291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression.
    Obermannová R; Van Cutsem E; Yoshino T; Bodoky G; Prausová J; Garcia-Carbonero R; Ciuleanu T; Garcia Alfonso P; Portnoy D; Cohn A; Yamazaki K; Clingan P; Lonardi S; Kim TW; Yang L; Nasroulah F; Tabernero J
    Ann Oncol; 2016 Nov; 27(11):2082-2090. PubMed ID: 27573561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOLFIRI® and bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms.
    Bécouarn Y; Cany L; Pulido M; Beyssac R; Texereau P; Le Morvan V; Béchade D; Brunet R; Aitouferoukh S; Lalet C; Mathoulin-Pélissier S; Fonck M; Robert J
    BMC Res Notes; 2014 Apr; 7():260. PubMed ID: 24758527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
    Gerger A; El-Khoueiry A; Zhang W; Yang D; Singh H; Bohanes P; Ning Y; Winder T; Labonte MJ; Wilson PM; Benhaim L; Paez D; El-Khoueiry R; Absenger G; Lenz HJ
    Clin Cancer Res; 2011 Sep; 17(17):5783-92. PubMed ID: 21791631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
    Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
    Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
    Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
    Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer.
    Degirmenci M; Karaca B; Gorumlu G; Durusoy R; Demir Piskin G; Bozkurt MT; Cirak Y; Tunali D; Karabulut B; Sanli UA; Uslu R
    Med Oncol; 2010 Sep; 27(3):585-91. PubMed ID: 19526201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.
    Personeni N; Rimassa L; Verusio C; Barni S; Rubino L; Bozzarelli S; Villa E; Carnaghi C; Tronconi MC; Gerardi C; Galli F; Floriani I; Destro A; Raschioni C; Labianca R; Santoro A
    Clin Colorectal Cancer; 2015 Sep; 14(3):162-9. PubMed ID: 25861836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.